Office for Technology Commercialization

Competing Endogenous RNA Databse for Drug Discovery and Development Research

Technology #20120303

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Drug Discovery and Development Research ceRNA DatabaseCompeting Endogenous RNA DatabaseMessenger RNA
Subbaya Subramanian, PhD
Assistant Professor, Department of Surgery, University of Minnesota
External Link (
Managed By
Andrew Morrow
Technology Licensing Officer

Competing Endogenous RNA Database Helps Establish Drug Targets

A database that encompasses all potential competing endogenous RNA (ceRNA) offers users a list of the ceRNAs and is in high demand by drug companies. The cost of bringing a drug to production is approximately $1 billion, with much of the cost residing in the drug discovery and development. This database would provide the initial information needed and help lower discovery costs. The database can help establish drug targets which are necessary in the development of new drugs.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Andrew Morrow for specific details.

Complete List of ceRNAs with mRNA and miRNA

A complete database of all the potential ceRNAs has not been developed before. The database allows users to access any potential ceRNA with a list which they can scroll through. Visual and descriptive output of all ceRNAs is given when a specific messenger RNA (mRNA) is chosen. The ceRNA database can be used to order the relevant micro RNAs (miRNA) in a specific disease by rank which is also given for each ceRNA. Use of this information in drug development is vital. It allows drug companies the capability to select the drug targets or alternative targets of undruggable gene products and identify mRNAs that can directly affect the ceRNAs. This is a new concept in miRNA mediated gene regulation. There remain endless possibilities to what the ceRNA database can accomplish.


  • No other database offers a list all potential ceRNAs with mRNA and miRNA
  • Helps to lower costs for drug companies in new drug discovery and development
  • Allows researchers to have mRNA and miRNA information at their fingertips
  • Aids in finding alternative drug gene targets